LAVA THERAPEUTICS NV (LVTX) Stock News
NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD
LVTX Latest News, Press Relases and Analysis
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to...
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA’s balance sheet Underscores focus on cost curtailment and strategic option...
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to...
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the second quarter of...
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the first quarter of ...
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial...
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson...
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips LAVA Therapeutics (NASDAQ:LVTX) just reported results for the fourth quarter of...
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage...
LAVA Reports Second Quarter 2024 Financial Results and Business Update
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab...
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage...
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
LAVA Announces Annual Meeting of Shareholders
UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage...
LAVA Announces Annual Meeting of Shareholders
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0...
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
LVTX stock results show that LAVA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for...
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023...
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!